Our global infrastructure supports the evolving demands of the clinical trial ecosystem. Store clinical drugs closer to key recruitment areas, reach patients faster, and keep your trials on track. Learn more.
The company hasn't determined whether its drug played a role in the deaths, but concerns over the treatment's safety could dim its chances for approval.
While small in size, the collaboration gives AstraZeneca an entry point into radiopharmaceutical drug research, which was the focus of two Novartis buyouts in recent years.
BioPharma Dive provides in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships.
BioPharma Dive is a leading industry publication operated by Industry Dive. Our business journalists spark ideas and shape agendas for 10+ million decision makers in the most competitive industries.
This email is optimized for display on mobile phones. BioPharma Dive: Daily Dive is a product of Industry Dive, Inc.. 1575 Eye St NW, 4th Floor, Washington, DC 20005. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to edwardlorilla1986.acciyo123@blogger.com. You can unsubscribe or switch to a weekly newsletter subscription anytime. See our full privacy policy.
0 Comments